Selexis names Yemi Onakunle as vp of strategic and market development
Former Diosynth and Lonza executive joins Swiss life science company
Onakunle has more than 15 years' experience in drug manufacturing and cell line development. Prior to joining Selexis, he was director of commercial development at Diosynth RTP and associate director of business development at Lonza Custom Manufacturing.
More recently, Onakunle was head of sales and marketing at Bachem Americas, a contract manufacturing organisation focusing on peptides and complex organic molecules.
Onakunle is a member of the board of directors of VLP Biotech, a vaccine development company based in San Diego, CA and has been a business advisor to several biopharmaceutical and drug delivery companies.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy